IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Aspire Private Capital LLC

Aspire Private Capital LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,957 shares of the medical research company’s stock after buying an additional 235 shares during the quarter. Aspire Private Capital LLC’s holdings in IQVIA were worth $684,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. AdvisorNet Financial Inc increased its stake in IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after buying an additional 95 shares during the period. BKM Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $32,000. Activest Wealth Management purchased a new stake in IQVIA during the 4th quarter worth about $35,000. CVA Family Office LLC acquired a new position in shares of IQVIA during the fourth quarter worth about $43,000. Finally, CoreFirst Bank & Trust acquired a new position in IQVIA during the 3rd quarter worth approximately $44,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,285 shares of company stock worth $10,331,003. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV traded up $3.25 during trading on Monday, hitting $231.34. 726,886 shares of the stock were exchanged, compared to its average volume of 963,590. The company has a fifty day moving average price of $244.82 and a two-hundred day moving average price of $222.04. The company has a market cap of $41.99 billion, a PE ratio of 31.73, a P/E/G ratio of 2.21 and a beta of 1.50. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the previous year, the business posted $2.54 earnings per share. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Analyst Ratings Changes

IQV has been the subject of a number of recent analyst reports. Barclays lifted their price target on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Robert W. Baird upped their price objective on shares of IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. SVB Leerink initiated coverage on IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price target on the stock. Evercore ISI upped their price target on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Finally, UBS Group upped their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.